TP53 and Miyoshi myopathy: Even though no single cell line model is likely to reflect all aspects of the consequences of TP53 lesions in MM patients, the AMO-1 system represented here has proven a robust and coherent model system for functional and pharmacological analysis of the consequences of single- and double-hits to TP53. Importantly, it implies that the different types of single-hit clones may already acquire considerable resilience against genotoxic drugs, but that this does not represent a primary resistance mechanism against other therapeutic approaches, such as proteasome inhibitors.